Literature DB >> 1005735

Failure of indomethacin to reduce hypercalcemia in patients with breast cancer.

R C Coombes, A M Neville, P K Bondy, T J Powles.   

Abstract

Prostaglandin synthetase inhibitors have, in the past, been shown to inhibit osteolysis caused by breast carcinoma tissue in vitro. We therefore assessed the effect of Indomethacin and aspirin on some parameters of calcium metabolism in patients with breast cancer. Neither drug reduced the serum calcium in pateints with hypercalcemia, nor reduced skeletal destruction as measured by the urinary hydroxy proline: creatinine ratio and urinary calcium in normocalcemic or hypercalcemic patients with osteolytic metastases. A possible reason for the discrepancy between results obtained in vitro and in vivo is that there are two phases of bone destruction in breast cancer; the early phase dependent and the late phase independent of prostaglandin synthesis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1005735     DOI: 10.1016/0090-6980(76)90136-2

Source DB:  PubMed          Journal:  Prostaglandins        ISSN: 0090-6980


  6 in total

Review 1.  Role of prostaglandins in bone metabolism: a review.

Authors:  D Atkins; M Greaves; K J Ibbotson; T J Martin
Journal:  J R Soc Med       Date:  1979-01       Impact factor: 5.344

Review 2.  Prostaglandin-mediated hypercalcemia: a paraneoplastic syndrome.

Authors:  H W Seyberth
Journal:  Klin Wochenschr       Date:  1978-04-15

3.  Calcium metabolism in breast cancer.

Authors:  R C Coombes; T J Powles; D G Joplin
Journal:  Proc R Soc Med       Date:  1977-03

Review 4.  Mechanisms for the development of bone metastases and hypercalcaemia in patients with breast cancer.

Authors:  T J Powles
Journal:  Proc R Soc Med       Date:  1977-03

Review 5.  Current management of malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

6.  Breast cancer, prostaglandins and patient survival.

Authors:  A Bennett; I F Stamford; D A Berstock; F Dische; L Singh; R P A'Hern
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.